This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           July 15, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Safety profile of HPV vaccines under review in Europe
The European Medicines Agency has started a review of human papillomavirus vaccines "to further clarify aspects of their safety profile," although the agency also points out that this review "does not question that the benefits of HPV vaccines outweigh their risks." The agency also notes that while the review is being carried out, no change in the use of these products is recommended.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


A phase II trial of trebananib, a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
Gynecologic Oncology (Subscription required)
Ang1 & 2 interact with Tie2 receptors on endothelial cells to mediate vascular remodeling in an angiogenesis signaling pathway distinct from the VEGF axis. Trebananib is a peptide Fc fusion protein that binds Ang1 and 2 and prevents interaction with Tie2. The efficacy of trebananib in recurrent/persistent endometrial cancer was studied. The results found that trebananib has insufficient single agent activity in recurrent EC to warrant further investigation at this dose/schedule.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer
Gynecologic Oncology (Subcription required)
Ovarian cancer is clinically characterized by advanced stage at presentation, transient chemosensitivity, and stagnant long-term survivorship rates despite a broadening portfolio of "active" therapies. Contemporary treatment standards of newly diagnosed patients dictate timely aggressive surgical cytoreduction followed by paclitaxel and platinum-based chemotherapy. Since "optimal" surgical outcome is no visible residual cancer, most of these favorable prognosis patients completing primary adjuvant chemotherapy will achieve complete clinical response.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Increased prevalence of comorbid conditions in women with uterine cancer
Gynecologic Oncology (Subscription required)
The objective of this study was to compare comorbidities of women with uterine cancer to controls so as to aid in development of survivorship care plans and programs. The conclusion was that multiple comorbid conditions, specifically those related to the metabolic syndrome, were more prevalent in UC survivors than in the general population, and this difference persisted after adjustment for age. UC survivorship programs should plan to allocate resources to account for these differences in healthcare needs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Female hormonal factors and the risk of endometrial cancer in Lynch syndrome
JAMA via MDLinx
Apart from hysterectomy, there is no consensus recommendation for reducing endometrial cancer risk for women with a mismatch repair gene mutation. To investigate the association between hormonal factors and endometrial cancer risk in Lynch syndrome. For women with a mismatch repair gene mutation, some endogenous and exogenous hormonal factors were associated with a lower risk of endometrial cancer. These directions and strengths of associations were similar to those for the general population. If replicated, these findings suggest that women with a mismatch repair gene mutation may be counseled like the general population in regard to hormonal influences on endometrial cancer risk.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


  Ovarian cancer updates from ASCO 2015:

4 prominent experts in ovarian cancer met in Chicago to provide perspectives related to progress made toward personalized therapy. More

Epirubicin, cisplatin, and capecitabine for primary platinum-resistant of platinum-refractory epithelial ovarian cancer
International Journal of Gynecological Cancer via MDLinx
Primary platinum–resistant epithelial ovarian cancer is an area of unmet medical need. There is limited evidence from small studies that platinum–based combinations can overcome "resistance" in a proportion of patients. The authors investigated the efficacy and toxicity of platinum–based combination chemotherapy in the platinum–resistant and platinum–refractory setting. Epirubicin, cisplatin, and capecitabine seems to be active in platinum–resistant relapsed EOC with manageable toxicity. Further prospective investigation of platinum–anthracycline combinations is warranted in patients who relapse 3 to 6 months after first–line platinum–taxane treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.

Protein in ovarian cancers deactivates immune system
Cancer Network
Data from a new study has shown that ovarian cancer progression may be driven by the activation of an endoplasmic reticulum stress response factor called XBP1, which disrupts the function of dendritic cells and, subsequently, antitumor fighting T cells.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Photoacoustic approach to breast cancer detection
University of Twente via Medical Xpress
Scientists at the research Institute MIRA at the University of Twente have been working for some time on a new technique to detect breast cancer. The technique, based on the physical principle of photoacoustics, has been christened PAMmography. It uses short bursts of light that generate ultrasonic waves in places with high density of blood vessels, such as in the vicinity of malignant tumors. The scientists present an important scientific step that they have taken with a publication in the journal Scientific Reports. They show that breast tumors have specific manifestations and forms in images made using their technique.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 8, 2015
July 1, 2015
June 24, 2015
June 17, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063